Navigation Links
Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
Date:7/25/2013

30, June 30, June 30, June 30, 2013 2012 2013 2012 Millions Millions Millions Millions Share based awards to employees (1) 11.0 6.3 9.1 4.5

  1. Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire's average share price during the calculation period or (b) the required performance conditions were not satisfied as at the balance sheet date.

Unaudited US GAAP results for the three months to June 30, 2013

Selected Notes to the Financial Statements

(2)  Analysis of revenues

3 months to June 30, 2013 2012 2013 2013 % % of total $M $M change revenue Net product sales: VYVANSE 300.3 266.2 13% 24% ELAPRASE 149.2 122.2 22% 12% LIALDA/MEZAVANT 137.5 94.1 46% 11% REPLAGAL 114.1 123.2 -7% 9% ADDERALL XR 112.3 133.9 -16% 9% INTUNIV 90.4 69.1 31% 7% VPRIV 82.5 82.7 0% 6% PENTASA 73.6 63.9 15% 6% FIRAZYR 49.5 31.7 56% 4% FOSRENOL 42.1 43.2 -3% 3% XAGRID(R) 26.5 25.5 4% 2% DERMAGRAFT 22.3 52.4 -57% 2% Other product sales 29.9 39.6 -24% 2% Total product sales 1,230.2 1,147.7 7% 97% Royalties: 3TC and ZEFFIX 11.3 10.6 7% 1% FOSRENOL 10.8 13.0 -17% 1% ADDERALL XR 4.9 25.7 -81% <1% Other 9.3 7.0 33% 1% Total royalties 36.3 56.3 -36% 3% Other revenues 8.0 3.8 111% <1% Total revenues 1,274.5 1,207.8 6% 100%

Unaudited US GAAP results for the six months to June 30, 2013

Selected Notes to the Financial Statements

(2)  Analysis of revenues

6 months to June 30, 2013 2012 2013 2013 % % of total $M $M change revenue Net product sales: VYVANSE 598.7 526.2 14% 24% ELAPRASE 263.5 247.8 6% 11% LIALDA/MEZAVANT 238.0 184.1 29% 10% REPLAGAL 228.1 257.6 -11% 9% ADDERALL XR 212.1 245.3 -14% 9% INTUNIV 168.1 137.6 22% 7% VPRIV 164.1 154.4 6% 7% PENTASA 144.6 129.7 11% 6% FIRAZYR 91.2 51.4 77% 4% FOSRENOL 84.4 88.7 -5% 3% XAGRID 49.9 48.7 2% 2% DERMAGRAFT 40.8 101.2 -60% 2% Other product sales 63.4 81
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
2. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
3. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
4. Shire Acquires Premacure AB
5. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
6. Shire Supports Rare Disease Day 2013
7. Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013
8. Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications
9. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
10. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
11. Dr Steven Gillis to Join Shire Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Presented at American Academy of Dermatology Summer ... NeoStrata today announced,findings from an ongoing 12-week ... applied LCD (coal tar) solution (Psorent(TM)) versus,calcipotriol ... psoriasis.,Specifically, results of an interim analysis reveal ...
... 30 An overwhelming number of,Americans with memory ... their,doctors despite visits within the past six months, ... participants in the Alzheimer,s Foundation of,America (AFA) National ... the results at a poster session at the ...
Cached Medicine Technology:Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 2Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 3Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 2Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 3
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... American Cancer Society,is looking for individuals with or without ... the battle against cancer to serve on peer,review committees ... the,organization,s research and training grants. These "stakeholders" have,often had ... had a,family member with cancer, having been a cancer ...
... will show that dental mercury uses contribute to high ... show, for the first time, that dental mercury air,emissions ... US EPA estimates, WASHINGTON, Nov.12 The U.S. ... Reform,Committee will hold a hearing on Wednesday, Nov. 14, ...
... 12 Leading health care risk,management and insurance ... for the period ended Sept. 30, 2007, including ... first nine months of the year. The ... insurance and integrated risk management products,and services for ...
... assistance services affect quality of,patient care, CHICAGO, ... is failing to provide language assistance services required,by ... with the Office for,Civil Rights of the U.S. ... was filed by the American Federation of State, ...
... French . , The Zaire species of Ebolavirus ... species. It alone is responsible for 88% of human ... 1976. It was moreover the species involved in the ... of Congo (DRC) .In spite of the mass of ...
... Nov. 12 Verus Pharmaceuticals, Inc., a,pediatric-oriented specialty pharmaceutical ... to President & Chief Executive Officer.,Prior to the promotion, ... a result of the promotion, Cam L. Garner now ... to announce this well-deserved promotion," said Cam L.,Garner. "As ...
Cached Medicine News:Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Language Assistance Lacking at Resurrection Hospitals 2Health News:Language Assistance Lacking at Resurrection Hospitals 3Health News:New genetic lineage of Ebola virus discovered in great apes 2Health News:New genetic lineage of Ebola virus discovered in great apes 3Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 2Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 3
... Cougar is an Anterior Spinal Implant ... elasticity approximating that of cortical bone. The ... structural requirements of anterior column support, while ... load sharing design. Incorporates an anatomic design ...
... anterior column support for single or multilevel ... L5. The system consists of one or ... are stacked to a desired height, accommodating ... Reinforced Polymer material emulates the biomechanical properties ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
Anterior Interbody fusion with proven clinical performance. Large hole design. Request info fda status for sale....
Medicine Products: